CARA Cara Therapeutics, Inc.

17.09
0  -1%
Previous Close 17.26
Open 17.48
Price To book 9.29
Market Cap 466.61M
Shares 27,303,000
Volume 1,342,006
Short Ratio 19.72
Av. Daily Volume 2,364,400

SEC filingsSee all SEC filings

  1. 8-K - Current report 17735400
  2. 424B5 - Prospectus (Rule 424(b)(5)) 17730284
  3. 424B5 - Prospectus (Rule 424(b)(5)) 17722462
  4. 8-K - Current report 17716921
  5. EFFECT - Notice of Effectiveness 17714079

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiated September 2015. Placed on clinical hold February 2016. Clinical hold released April 2016 with enrollment resuming June 2016. Interim conditional power analysis due 2Q 2017.
IV CR845
Acute pain
Phase 2b trial initiated September, 2016. Data are due 2Q 2017.
CR845
Osteoarthritis (OA)
Phase 2/3 top-line data from Part A portion of trial released March 28, 2017 - endpoints met. Part B to be initiated later in 2017.
IV CR845
Uremic pruritus